Shortening treatment for tuberculosis--to basics
- PMID: 25337754
- DOI: 10.1056/NEJMe1410977
Shortening treatment for tuberculosis--to basics
Comment on
-
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426. Epub 2014 Sep 7. N Engl J Med. 2014. PMID: 25196020 Free PMC article. Clinical Trial.
-
A four-month gatifloxacin-containing regimen for treating tuberculosis.N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817. N Engl J Med. 2014. PMID: 25337748 Clinical Trial.
-
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210. N Engl J Med. 2014. PMID: 25337749 Free PMC article. Clinical Trial.
Similar articles
-
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl J Med. 2015 Feb 5;372(6):577. doi: 10.1056/NEJMc1414718. N Engl J Med. 2015. PMID: 25651258 No abstract available.
-
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl J Med. 2015 Feb 5;372(6):576. doi: 10.1056/NEJMc1414718. N Engl J Med. 2015. PMID: 25651257 No abstract available.
-
Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment.Evid Based Med. 2015 Aug;20(4):128-9. doi: 10.1136/ebmed-2014-110139. Epub 2015 Apr 29. Evid Based Med. 2015. PMID: 25926523 No abstract available.
-
Diagnosis and management of tuberculosis.Prim Care. 1979 Mar;6(1):43-62. Prim Care. 1979. PMID: 111269 Review. No abstract available.
-
Bacteriologic basis of short-course chemotherapy for tuberculosis.Clin Chest Med. 1980 May;1(2):231-41. Clin Chest Med. 1980. PMID: 6794976 Review. No abstract available.
Cited by
-
An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis.Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2318003121. doi: 10.1073/pnas.2318003121. Epub 2024 May 1. Proc Natl Acad Sci U S A. 2024. PMID: 38691588 Free PMC article.
-
TZD-Based Hybrid Molecules Act as Dual Anti-Mycobacterium tuberculosis and Anti-Toxoplasma gondii Agents.Int J Mol Sci. 2023 Jan 20;24(3):2069. doi: 10.3390/ijms24032069. Int J Mol Sci. 2023. PMID: 36768392 Free PMC article.
-
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel). 2022 Jul 27;9(8):1120. doi: 10.3390/children9081120. Children (Basel). 2022. PMID: 36010011 Free PMC article. Review.
-
Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.Pharmaceutics. 2022 Jun 30;14(7):1383. doi: 10.3390/pharmaceutics14071383. Pharmaceutics. 2022. PMID: 35890280 Free PMC article. Review.
-
Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis.PLoS Pathog. 2022 Feb 8;18(2):e1009862. doi: 10.1371/journal.ppat.1009862. eCollection 2022 Feb. PLoS Pathog. 2022. PMID: 35134095 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources